Sun, 01 Nov 2026
03:14:04 pm
Rudransh Sangwan
Published at: September 17, 2026, 11:42 AM
Synopsis
Tata Motors PV shares gained after reports of Chandrasekaran's fresh term at Tata Sons. See the leadership update, price hike and key stock factors.

Tata Motors Passenger Vehicles shares rose 4.52% to around Rs 315 on September 17 after reports that Tata Sons approved a fresh five year term for N Chandrasekaran as executive chairman.
Tata Motors also announced a price increase of up to 1% across its commercial vehicle range from October 1 to offset higher input costs.
| Metric | TMPV |
|---|---|
| Share price | Rs 315 |
| Daily gain | 4.52% |
| Market capitalisation | Rs 1.16 lakh crore |
| 52 week high | Rs 447 |
| 52 week low | Rs 294 |
| P/E | 116 |
| Book value | Rs 304 |
| ROE | 75.7% |
| ROCE | 2.73% |
| Dividend yield | 0.95% |
| Face value | Rs 2 |
{{CHART}}
| Driver | Details |
|---|---|
| Chandrasekaran extension | Tata Sons board approved a fresh five year term, according to reports |
| Tata Group sentiment | Major Tata stocks gained following the leadership development |
| Commercial vehicle price hike | Prices to rise up to 1% from October 1 |
| Input cost pressure | Price increase aims to offset higher commodity and other input costs |
| Leadership continuity | Investors responded to greater clarity around Tata Group leadership |
Tata Motors Passenger Vehicles was among the Tata Group stocks that rose sharply during the session. Tata Group stocks gained following the leadership development.
| Particular | Details |
|---|---|
| Segment | Commercial vehicles |
| Price increase | Up to 1% |
| Effective date | October 1, 2026 |
| Reason | Higher commodity and input costs |
| Coverage | Entire commercial vehicle range |
| Model impact | Varies by model and variant |
The latest increase follows price hikes of up to 2.5% in June and 1.5% in March. Tata Motors remains among the key Tata Group stocks tracked by investors. Tata Group stocks have also been in focus during recent market sessions.
| Development | Details |
|---|---|
| Executive chairman | N Chandrasekaran |
| New term | Five years |
| Earlier term end | February 20, 2027 |
| Tata Sons decision | Fresh reappointment approved by board |
| Market reaction | Tata Group stocks gained |
| Other development | Tata Sons has initiated steps toward a potential listing, according to reports |
The reported reappointment provides greater clarity on Tata Group leadership beyond February 2027, subject to the required approval process. Tata Sons remains central to the group's listed companies and its potential listing discussions.
| Factor | What to track |
|---|---|
| Passenger vehicle sales | Monthly volumes and market share |
| EV business | New launches and demand |
| Commercial vehicle prices | Impact on margins and demand |
| Input costs | Steel, aluminium and other commodities |
| Tata Group leadership | Further developments around Chandrasekaran's term |
| Stock valuation | Earnings growth relative to P/E |
| JLR business | Global demand and profitability |
Investors will track vehicle sales, EV demand, input costs, margins and further developments around Tata Group leadership. Tata Motors will remain in focus alongside other Tata Group companies.

Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.

Motilal Oswal Q2 FY27 results show net profit rising 198% to ₹1,080 crore, revenue increasing 64% to ₹3,040 crore and EBITDA margin reaching 60.37%.

Bliss GVS Pharma Q2 FY27 results show revenue rising 37.3% to ₹261.13 crore, EBITDA jumping 161.4% and net profit increasing 196%.

Alivus Life Sciences Q2 FY27 results show net profit rising 51.3% to ₹196.8 crore, revenue growing 16% to ₹682 crore and EBITDA margin reaching 38.

Thyrocare Q2 FY27 revenue rose 25.1% to ₹270.81 crore, while net profit fell 66.9% to ₹15.89 crore amid a ₹44.98 crore impairment loss.

Patel Retail will invest ₹2 crore to add 20,000 sq ft to its Ambernath distribution centre, increasing covered area to 84,000 sq ft.